Click Here for 5% Off Your First Aladdin Purchase!

Resveratrol - analytical standard, high purity , CAS No.501-36-0, Inhibitor of COX-2;Agonist of TAS2R14;Antagonist of Peroxisome proliferator-activated receptor-γ

  • analytical standard
  • Moligand™
Item Number
R107314
Grouped product items
SKUSizeAvailabilityPrice Qty
R107314-100mg
100mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$90.90

Antioxidant polyphenol with a multitude of biological activities

Basic Description

Synonymsresveratrol|501-36-0|trans-resveratrol|3,4',5-Trihydroxystilbene|(E)-5-(4-Hydroxystyryl)benzene-1,3-diol|3,5,4'-Trihydroxystilbene|(E)-resveratrol|Resvida|3,4',5-Stilbenetriol|5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol|3,4',5-Trihydroxy-trans-stil
Specifications & PurityMoligand™, analytical standard
Biochemical and Physiological MechanismsResveratrol is a phenolic phytoalexin found in grape skin and other plants. Resveratrol produced neurotrophic effects on cultured DA neurons. Resveratrol could attenuate oxidant-induced mitochondrial damage in embryonic rat cardiomyocytes by inactivating
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
Gradeanalytical standard, Moligand™
Action TypeAGONIST, ANTAGONIST, INHIBITOR
Mechanism of actionInhibitor of COX-2;Agonist of TAS2R14;Antagonist of Peroxisome proliferator-activated receptor-γ
NoteWherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

Associated Targets

CYP1A2 Tchem Cytochrome P450 1A2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP1B1 Tchem Cytochrome P450 1B1 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP20A1 Tbio Cytochrome P450 20A1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD2 Tclin D(2) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP3A4 Tclin Cytochrome P450 3A4 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ERBB2 Tclin Receptor tyrosine-protein kinase erbB-2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ELANE Tclin Neutrophil elastase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EGFR Tclin Epidermal growth factor receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HMGCR Tclin 3-hydroxy-3-methylglutaryl-coenzyme A reductase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HDAC6 Tclin Histone deacetylase 6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HDAC2 Tclin Histone deacetylase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HRH1 Tclin Histamine H1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLCO1B3 Tchem Solute carrier organic anion transporter family member 1B3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLC6A4 Tclin Sodium-dependent serotonin transporter 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

TRPA1 Tclin Transient receptor potential cation channel subfamily A member 1 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SIGMAR1 Tclin Sigma non-opioid intracellular receptor 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

TTR Tclin Transthyretin 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PIK3CB Tchem Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PDE4D Tclin cAMP-specific 3',5'-cyclic phosphodiesterase 4D 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PTGS1 Tclin Prostaglandin G/H synthase 1 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CA2 Tclin Carbonic anhydrase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CA4 Tclin Carbonic anhydrase 4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP19A1 Tclin Aromatase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BCL2L1 Tchem Bcl-2-like protein 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2B Tclin Alpha-2B adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2C Tclin Alpha-2C adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR2A Tclin 5-hydroxytryptamine receptor 2A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA2A Tclin Adenosine receptor A2a 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ACHE Tclin Acetylcholinesterase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ABL1 Tclin Tyrosine-protein kinase ABL1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AR Tclin Androgen receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AKT1 Tchem RAC-alpha serine/threonine-protein kinase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AKR1B1 Tclin Aldose reductase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

APP Tclin Amyloid-beta A4 protein 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA1 Tclin Adenosine receptor A1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR1A Tclin 5-hydroxytryptamine receptor 1A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA3 Tchem Adenosine receptor A3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR2B Tclin 5-hydroxytryptamine receptor 2B 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

F2 Tclin Prothrombin 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BCHE Tclin Cholinesterase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EDNRA Tclin Endothelin-1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCNH2 Tclin Potassium voltage-gated channel subfamily H member 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRK1 Tclin Kappa-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRM1 Tclin Mu-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NOS2 Tchem Nitric oxide synthase, inducible 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NOS1 Tchem Nitric oxide synthase, brain 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MTOR Tclin Serine/threonine-protein kinase mTOR 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
INCHI InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
InChi Key LUKBXSAWLPMMSZ-OWOJBTEDSA-N
Canonical SMILES C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
Isomeric SMILES C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O
WGK Germany 3
RTECS CZ8987000
Alternate CAS 501-36-0
PubChem CID 445154
NSC Number 327430
MeSH Entry Terms 3,4',5-stilbenetriol;3,4',5-Trihydroxystilbene;3,5,4'-trihydroxystilbene;cis Resveratrol;cis-resveratrol;resveratrol;Resveratrol 3 sulfate;Resveratrol, (Z)-;resveratrol-3-sulfate;SRT 501;SRT-501;SRT501;trans Resveratrol;trans Resveratrol 3 O sulfate;trans
Molecular Weight 228.24

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

1 results found

Lot NumberCertificate TypeDateItem
H1617086Certificate of AnalysisDec 20, 2023 R107314

Chemical and Physical Properties

Melt Point(°C)267 °C

Safety and Hazards(GHS)

Pictogram(s) GHS07
Signal Warning
Hazard Statements

H319:Causes serious eye irritation

Precautionary Statements

P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes.

P337+P317:If eye irritation persists: Get medical help.

WGK Germany 3
RTECS CZ8987000
Merck Index 8158

Related Documents

References

1. Kode A, Rajendrasozhan S, Caito S, Yang SR, Megson IL, Rahman I.  (2008)  Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells..  Am J Physiol Lung Cell Mol Physiol,  294  (3): (L478-88).  [PMID:18162601]
2. Ungvari Z, Bagi Z, Feher A, Recchia FA, Sonntag WE, Pearson K, de Cabo R, Csiszar A.  (2010)  Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2..  Am J Physiol Heart Circ Physiol,  299  (1): (H18-24).  [PMID:20418481]
3. Rizvi SI, Pandey KB.  (2010)  Activation of the erythrocyte plasma membrane redox system by resveratrol: a possible mechanism for antioxidant properties..  Pharmacol Rep,  62  (4): (726-32).  [PMID:20885013]
4. Kelsey NA, Wilkins HM, Linseman DA.  (2010)  Nutraceutical antioxidants as novel neuroprotective agents..  Molecules,  15  (11): (7792-814).  [PMID:21060289]
5. Speciale A, Chirafisi J, Saija A, Cimino F.  (2011)  Nutritional antioxidants and adaptive cell responses: an update..  Curr Mol Med,  11  (9): (770-89).  [PMID:21999148]
6. Voloshyna I, Hai O, Littlefield MJ, Carsons S, Reiss AB.  (2013)  Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARγ and adenosine..  Eur J Pharmacol,  698  (1-3): (299-309).  [PMID:23041272]
7. St John SE, Jensen KC, Kang S, Chen Y, Calamini B, Mesecar AD, Lipton MA.  (2013)  Design, synthesis, biological and structural evaluation of functionalized resveratrol analogues as inhibitors of quinone reductase 2..  Bioorg Med Chem,  21  (19): (6022-37).  [PMID:23953689]
8. Zordoky BN, Robertson IM, Dyck JR.  (2015)  Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases..  Biochim Biophys Acta,  1852  (6): (1155-77).  [PMID:25451966]
9. Ma T, Tan MS, Yu JT, Tan L.  (2014)  Resveratrol as a therapeutic agent for Alzheimer's disease..  Biomed Res Int,  2014  (3): (350516).  [PMID:25525597]
10. Park EJ, Pezzuto JM.  (2015)  The pharmacology of resveratrol in animals and humans..  Biochim Biophys Acta,  1852  (6): (1071-113).  [PMID:25652123]
11. Vahid F, Zand H, Nosrat-Mirshekarlou E, Najafi R, Hekmatdoost A.  (2015)  The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review..  Gene,  562  (1): (8-15).  [PMID:25701602]
12. Han G, Xia J, Gao J, Inagaki Y, Tang W, Kokudo N.  (2015)  Anti-tumor effects and cellular mechanisms of resveratrol..  Drug Discov Ther,  (1): (1-12).  [PMID:25788047]
13. Britton RG, Kovoor C, Brown K.  (2015)  Direct molecular targets of resveratrol: identifying key interactions to unlock complex mechanisms..  Ann N Y Acad Sci,  1348  (1): (124-33).  [PMID:26099829]
14. Fu W, Zhuang W, Zhou S, Wang X.  (2015)  Plant-derived neuroprotective agents in Parkinson's disease..  Am J Transl Res,  (7): (1189-202).  [PMID:26328004]
15. Gong WH, Zhao N, Zhang ZM, Zhang YX, Yan L, Li JB.  (2017)  The inhibitory effect of resveratrol on COX-2 expression in human colorectal cancer: a promising therapeutic strategy..  Eur Rev Med Pharmacol Sci,  21  (5): (1136-1143).  [PMID:28338176]
16. Bariani MV, Correa F, Leishman E, Domínguez Rubio AP, Arias A, Stern A, Bradshaw HB, Franchi AM.  (2017)  Resveratrol protects from lipopolysaccharide-induced inflammation in the uterus and prevents experimental preterm birth..  Mol Hum Reprod,  23  (8): (571-581).  [PMID:28810692]
17. Kong F, Zhang R, Zhao X, Zheng G, Wang Z, Wang P.  (2017)  Resveratrol raisesin vitroanticancer effects of paclitaxel in NSCLC cell line A549 through COX-2 expression..  Korean J Physiol Pharmacol,  21  (5): (465-474).  [PMID:28883751]
18. Buhrmann C, Popper B, Aggarwal BB, Shakibaei M.  (2017)  Resveratrol downregulates inflammatory pathway activated by lymphotoxin α (TNF-β) in articular chondrocytes: Comparison with TNF-α..  PLoS ONE,  12  (11): (e0186993).  [PMID:29095837]
19. Afewerky HK et al..  (2022)  Sodium-calcium exchanger isoform-3 targeted Withania somnifera (L.) Dunal therapeutic intervention ameliorates cognition in the 5xFAD mouse model of Alzheimer's disease..  Sci Rep,  12  (1537).  [PMID:35087161]
20. Yao ZQ et al..  (2018)  A novel small-molecule activator of Sirtuin-1 induces autophagic cell death/mitophagy as a potential therapeutic strategy in glioblastoma..  Cell Death Dis,  (7): (767).  [PMID:29991742]
21. Campo VA.  (2017)  Comparative effects of histone deacetylases inhibitors and resveratrol on Trypanosoma cruzi replication, differentiation, infectivity and gene expression..  Int J Parasitol Drugs Drug Resist,  (23-33).  [PMID:28038431]
22. Nevoral J et al..  (2019)  Epigenetic and non-epigenetic mode of SIRT1 action during oocyte meiosis progression..  J Anim Sci Biotechnol,  10  (67).  [PMID:31413827]
23. Guo D et al..  (2018)  Resveratrol protects early brain injury after subarachnoid hemorrhage by activating autophagy and inhibiting apoptosis mediated by the Akt/mTOR pathway..  Neuroreport,  29  (5): (368-379).  [PMID:29360689]
24. Adamkova K et al..  (2017)  SIRT1-dependent modulation of methylation and acetylation of histone H3 on lysine 9 (H3K9) in the zygotic pronuclei improves porcine embryo development..  J Anim Sci Biotechnol,  (83).  [PMID:29118980]

Solution Calculators